Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
2000 1
2001 2
2002 1
2003 3
2004 4
2005 1
2006 4
2007 7
2008 4
2009 4
2010 15
2011 9
2012 14
2013 17
2014 11
2015 12
2016 14
2017 17
2018 10
2019 16
2020 12
2021 17
2022 19
2023 14

Text availability

Article attribute

Article type

Publication date

Search Results

209 results

Results by year

Filters applied: . Clear all
Page 1
Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group.
[No authors listed] [No authors listed] Mov Disord. 1996 Mar;11(2):136-42. doi: 10.1002/mds.870110204. Mov Disord. 1996. PMID: 8684382
The Unified Huntington's Disease Rating Scale (UHDRS) was developed as a clinical rating scale to assess four domains of clinical performance and capacity in HD: motor function, cognitive function, behavioral abnormalities, and functional capacity. We assessed the internal …
The Unified Huntington's Disease Rating Scale (UHDRS) was developed as a clinical rating scale to assess four domains of clinical per …
Potential disease-modifying therapies for Huntington's disease: lessons learned and future opportunities.
Tabrizi SJ, Estevez-Fraga C, van Roon-Mom WMC, Flower MD, Scahill RI, Wild EJ, Muñoz-Sanjuan I, Sampaio C, Rosser AE, Leavitt BR. Tabrizi SJ, et al. Lancet Neurol. 2022 Jul;21(7):645-658. doi: 10.1016/S1474-4422(22)00121-1. Lancet Neurol. 2022. PMID: 35716694 Free PMC article. Review.
Huntington's disease is the most frequent autosomal dominant neurodegenerative disorder; however, no disease-modifying interventions are available for patients with this disease. ...Potential interventions for Huntington's disease include therapies targeting hunting …
Huntington's disease is the most frequent autosomal dominant neurodegenerative disorder; however, no disease-modifying interventions …
Huntington Study Group Abstracts 2020.
[No authors listed] [No authors listed] Neurotherapeutics. 2020 Dec;17(Suppl 1):1-41. doi: 10.1007/s13311-020-00945-z. Neurotherapeutics. 2020. PMID: 33083994 Free PMC article. No abstract available.
Preventing Parkinson's Disease: An Environmental Agenda.
De Miranda BR, Goldman SM, Miller GW, Greenamyre JT, Dorsey ER. De Miranda BR, et al. J Parkinsons Dis. 2022;12(1):45-68. doi: 10.3233/JPD-212922. J Parkinsons Dis. 2022. PMID: 34719434 Free PMC article. Review.
Treatment of Tardive Dyskinesia.
Bashir HH, Jankovic J. Bashir HH, et al. Neurol Clin. 2020 May;38(2):379-396. doi: 10.1016/j.ncl.2020.01.004. Epub 2020 Feb 28. Neurol Clin. 2020. PMID: 32279716 Review.
Correction to: Huntington Study Group Abstracts 2020.
[No authors listed] [No authors listed] Neurotherapeutics. 2020 Dec;17(Suppl 1):42. doi: 10.1007/s13311-020-00970-y. Neurotherapeutics. 2020. PMID: 33200289 Free PMC article. No abstract available.
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM; Huntington Study Group/ARC-HD Investigators and Coordinators. Frank S, et al. CNS Drugs. 2022 Nov;36(11):1207-1216. doi: 10.1007/s40263-022-00956-8. Epub 2022 Oct 15. CNS Drugs. 2022. PMID: 36242718 Free PMC article. Clinical Trial.
METHODS: This open-label, single-arm, multi-center study included patients who completed a double-blind study (Rollover) and patients who converted overnight from a stable tetrabenazine dose (Switch). ...Efficacy was analyzed using a stable post-titration timepoint …
METHODS: This open-label, single-arm, multi-center study included patients who completed a double-blind study (Rollover) and p …
CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset.
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Electronic address: gusella@helix.mgh.harvard.edu; Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Electronic address: gusella@helix.mgh.harvard.edu, et al. Cell. 2019 Aug 8;178(4):887-900.e14. doi: 10.1016/j.cell.2019.06.036. Cell. 2019. PMID: 31398342 Free PMC article.
Variable, glutamine-encoding, CAA interruptions indicate that a property of the uninterrupted HTT CAG repeat sequence, distinct from the length of huntingtin's polyglutamine segment, dictates the rate at which Huntington's disease (HD) develops. The timing of onset shows n …
Variable, glutamine-encoding, CAA interruptions indicate that a property of the uninterrupted HTT CAG repeat sequence, distinct from the len …
Burden of Neurological Disorders Across the US From 1990-2017: A Global Burden of Disease Study.
GBD 2017 US Neurological Disorders Collaborators; Feigin VL, Vos T, Alahdab F, Amit AML, Bärnighausen TW, Beghi E, Beheshti M, Chavan PP, Criqui MH, Desai R, Dhamminda Dharmaratne S, Dorsey ER, Wilder Eagan A, Elgendy IY, Filip I, Giampaoli S, Giussani G, Hafezi-Nejad N, Hole MK, Ikeda T, Owens Johnson C, Kalani R, Khatab K, Khubchandani J, Kim D, Koroshetz WJ, Krishnamoorthy V, Krishnamurthi RV, Liu X, Lo WD, Logroscino G, Mensah GA, Miller TR, Mohammed S, Mokdad AH, Moradi-Lakeh M, Morrison SD, Shivamurthy VKN, Naghavi M, Nichols E, Norrving B, Odell CM, Pupillo E, Radfar A, Roth GA, Shafieesabet A, Sheikh A, Sheikhbahaei S, Shin JI, Singh JA, Steiner TJ, Stovner LJ, Wallin MT, Weiss J, Wu C, Zunt JR, Adelson JD, Murray CJL. GBD 2017 US Neurological Disorders Collaborators, et al. JAMA Neurol. 2021 Feb 1;78(2):165-176. doi: 10.1001/jamaneurol.2020.4152. JAMA Neurol. 2021. PMID: 33136137 Free PMC article.
DESIGN, SETTING, AND PARTICIPANTS: This is a systematic analysis of the Global Burden of Disease (GBD) 2017 study. Data on incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) of major neurological disorders were derived from the GBD 2017 study …
DESIGN, SETTING, AND PARTICIPANTS: This is a systematic analysis of the Global Burden of Disease (GBD) 2017 study. Data on incidence, …
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.
Huntington Study Group; Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E. Huntington Study Group, et al. JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655. JAMA. 2016. PMID: 27380342 Free article. Clinical Trial.
OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease. DESIGN, SETTING, AND PARTICIPANTS: Ninety ambulatory adults diagnosed with manifest Huntington disease and a baseline total maximal chorea …
OBJECTIVE: To evaluate efficacy and safety of deutetrabenazine treatment to control chorea associated with Huntington disease. DESIGN …
209 results